3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
46
Kidney Neoplasms
11
Carcinoma, Renal Cell
11
Urinary Bladder Neoplasms
9
Neoplastic Cells, Circulating
8
Neoplasms
8
Breast Neoplasms
7
Neoplasm Metastasis
5
Melanoma
5
Sarcoma
4
Carcinoma, Non-Small-Cell Lung
4
Testicular Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Disease
3
Colorectal Neoplasms
3
von Hippel-Lindau Disease
2
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Prostatic Hyperplasia
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Liver Neoplasms
2
Leukemia
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Clear-cell metastatic renal cell carcinoma
2
Interventions
enzalutamide
10
Abiraterone Acetate
6
rucaparib
2
Prednisone
2
Docetaxel
2
tildrakizumab
1
sabizabulin
1
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Blood Specimen Collection
1
Biopsy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer
×
Blood Specimen Collection
×
Genitourinary
×
Clear all
NCT02424448
2016-07-26
BIOMETHS
The Christie NHS Foundation Trust
Completed
6 enrolled